Granite Investment Partners LLC boosted its stake in shares of Cytosorbents Corp (NASDAQ:CTSO) by 87.8% during the first quarter, Holdings Channel reports. The fund owned 110,530 shares of the medical research company’s stock after acquiring an additional 51,679 shares during the period. Granite Investment Partners LLC’s holdings in Cytosorbents were worth $837,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the business. BlackRock Inc. raised its stake in shares of Cytosorbents by 1.2% in the 4th quarter. BlackRock Inc. now owns 1,985,640 shares of the medical research company’s stock valued at $16,046,000 after purchasing an additional 23,891 shares in the last quarter. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 28.3% in the 1st quarter. Skylands Capital LLC now owns 636,050 shares of the medical research company’s stock worth $4,815,000 after acquiring an additional 140,200 shares during the period. Geode Capital Management LLC lifted its stake in shares of Cytosorbents by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 301,498 shares of the medical research company’s stock worth $2,436,000 after acquiring an additional 16,679 shares during the period. United Services Automobile Association lifted its stake in Cytosorbents by 47.1% during the fourth quarter. United Services Automobile Association now owns 281,903 shares of the medical research company’s stock valued at $2,278,000 after purchasing an additional 90,300 shares during the last quarter. Finally, Sargent Investment Group LLC acquired a new stake in Cytosorbents during the fourth quarter valued at approximately $2,015,000. 26.43% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:CTSO opened at $6.00 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.70 and a quick ratio of 3.52. The company has a market capitalization of $198.01 million, a P/E ratio of -10.71 and a beta of 1.55. Cytosorbents Corp has a 52 week low of $5.96 and a 52 week high of $14.95.
Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Tuesday, May 7th. The medical research company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The business had revenue of $5.19 million during the quarter, compared to the consensus estimate of $6.03 million. Cytosorbents had a negative net margin of 83.93% and a negative return on equity of 103.90%. On average, research analysts expect that Cytosorbents Corp will post -0.56 earnings per share for the current year.
CTSO has been the subject of several recent research reports. ValuEngine lowered shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Monday, April 15th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Cytosorbents in a research note on Friday, March 8th. Finally, Maxim Group reissued a “buy” rating and set a $18.00 target price on shares of Cytosorbents in a research note on Friday, March 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $14.67.
TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/13/cytosorbents-corp-nasdaqctso-shares-bought-by-granite-investment-partners-llc.html.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Featured Article: Investing in Growth Stocks
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Corp (NASDAQ:CTSO).
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.